Acelrx Pharmaceuticals IncのP / E
Acelrx Pharmaceuticals IncのP / Eは何ですか。
Acelrx Pharmaceuticals IncのP / Eは0.00です。
P / Eの定義は何ですか。
株価収益率 (P/E)は、会社の株価と会社の1株当たり利益との比率であり、末尾12ヶ月間にわたって計算されます。
The price to earnings ratio is the most widely used method for determining whether shares are accurately valued in relation to one another. But the P/E ratio does not in itself indicate whether the share is a bargain. The P/E ratio depends on the market’s perception of the risk and future growth in earnings. A company with a low P/E ratio indicates that the market perceives it as a higher risk or a lower growth or both as compared to a company with a higher price to earnings ratio. The P/E ratio of a listed company’s stock is the result of the collective perception of the market as to how risky the company is and what its earnings growth prospects are in relation to that of other companies. Investors use the P/E ratio to compare their own perception of the risk and growth of a company against the market’s collective perception of the risk and growth as reflected in the current P/E ratio.
NASDAQのセクタHealth CareにおけるP / Eの企業と比べるAcelrx Pharmaceuticals Inc
Acelrx Pharmaceuticals Incは何をしますか。
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v
Acelrx Pharmaceuticals Incと類似のp / e
- Richland Resources InternationalのP / EはN/Aです。
- Safeplus InternationalのP / EはN/Aです。
- China Yanyuan Yuhui Natl Ed GrpのP / EはN/Aです。
- AcusphereのP / EはN/Aです。
- American Oriental BioengineeringのP / EはN/Aです。
- Gourmet Provisions InternationalのP / EはN/Aです。
- Acelrx Pharmaceuticals IncのP / Eは0.00です。
- SEL ManufacturingのP / Eは0.00です。
- China Zhong Qi HldgsのP / Eは0.00です。
- MedSmartのP / Eは0.00です。
- Panbela TherapeuticsのP / Eは0.00です。
- EpicのP / Eは0.00です。
- 2574のP / Eは0.00です。